Top

Published in:

Open Access 01-12-2021 | Statins | Research article

Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study

Authors: Madeline N. Peterson, Hayley J. Dykhoff, Cynthia S. Crowson, John M. Davis III, Lindsey R. Sangaralingham, Elena Myasoedova

Published in: Arthritis Research & Therapy | Issue 1/2021

Abstract

Objective

To evaluate the association between statin use and the risk of developing rheumatoid arthritis (RA) in a large, US case-control study.

Methods

Using the OptumLabs Data Warehouse, RA cases were identified as patients aged ≥18 years with ≥2 RA diagnoses between January 1, 2010 and June 30, 2019 and ≥1 prescription fills for methotrexate within 1 year of the first RA diagnosis. The first RA diagnosis was the index date. Cases were matched 1:1 to controls on age, sex, region, year of index date, and length of baseline coverage. Statin users were defined by having ≥2 statin prescription fills at least 90 days pre-index. Patients identified as statin users were further classified by statin user status (current or former), statin use duration, and intensity of statin exposure. Odds ratios for RA risk with statin use were estimated using logistic regression.

Results

16,363 RA cases and 16,363 matched controls were identified. Among RA cases, 5509 (33.7%) patients were statin users compared to 5164 (31.6%) of the controls. Statin users had a slightly increased risk of RA compared to non-users (OR 1.12, 95% CI 1.06–1.18), and former statin users had an increased RA risk compared to current users (OR 1.21, 95% CI 1.13–1.28). However, risk was eliminated following adjustment for hyperlipidemia. The risk estimates for statin use duration and intensity did not reach significance.

Conclusion

This study demonstrates no significant increase in the risk of developing RA for statin users compared to non-users after adjustment for hyperlipidemia in addition to other relevant confounders. However, more information from prospective studies would be necessary to further understand this relationship.

Available only for authorised users

Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. Jama. 2015;314(17):1818–31. https://doi.org/10.1001/jama.2015.13766.CrossRefPubMedPubMedCentral

Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160–4. https://doi.org/10.1126/science.1059344.CrossRefPubMed

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.CrossRefPubMed

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.CrossRefPubMed

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57. https://doi.org/10.1056/NEJM199811053391902.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. https://doi.org/10.1001/jama.279.20.1615.CrossRefPubMed

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748.CrossRefPubMedPubMedCentral

Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum. 2006;54(2):393–407. https://doi.org/10.1002/art.21521.CrossRefPubMed

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–82. https://doi.org/10.1016/S0140-6736(09)60447-5.CrossRefPubMed

10.

Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215–25. https://doi.org/10.1016/j.autrev.2017.10.013.CrossRefPubMed

11.

Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2015;33(1):69–76.PubMed

12.

Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34(5):964–8.PubMed

13.

Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, González-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003;12(8):607–11. https://doi.org/10.1191/0961203303lu429oa.CrossRefPubMed

14.

McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363(9426):2015–21. https://doi.org/10.1016/S0140-6736(04)16449-0.CrossRefPubMed

15.

Mowla K, Rajai E, Ghorbani A, Dargahi-Malamir M, Bahadoram M, Mohammadi S. Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: double-blind randomized controlled trial. J Clin Diagn Res. 2016;10(5):Oc32–6.PubMedPubMedCentral

16.

Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52(5):1023–32. https://doi.org/10.1194/jlr.M010876.CrossRefPubMedPubMedCentral

17.

Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17–24. https://doi.org/10.1111/j.1468-3083.2006.01838.x.CrossRefPubMed

18.

de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis. 2012;71(5):648–54. https://doi.org/10.1136/ard.2011.155622.CrossRefPubMed

19.

de Jong HJI, Cohen Tervaert JW, Lalmohamed A, de Vries F, Vandebriel RJ, van Loveren H, et al. Pattern of risks of rheumatoid arthritis among patients using statins: a cohort study with the clinical practice research datalink. PLoS ONE. 2018;13(2):e0193297. https://doi.org/10.1371/journal.pone.0193297.CrossRefPubMedPubMedCentral

20.

Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med. 2010;7(9):e1000336. https://doi.org/10.1371/journal.pmed.1000336.CrossRefPubMedPubMedCentral

21.

Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):546–51. https://doi.org/10.1136/ard.2008.091967.CrossRefPubMed

22.

Tascilar K, Dell'Aniello S, Hudson M, Suissa S. Statins and risk of rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol. 2016;68(11):2603–11. https://doi.org/10.1002/art.39774.CrossRefPubMed

23.

Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Bmj. 2010;340(may19 4):c2197. https://doi.org/10.1136/bmj.c2197.CrossRefPubMedPubMedCentral

24.

Schmidt T, Battafarano DF, Mortensen EM, Frei CR, Mansi I. Frequency of development of connective tissue disease in statin-users versus nonusers. Am J Cardiol. 2013;112(6):883–8. https://doi.org/10.1016/j.amjcard.2013.04.059.CrossRefPubMed

25.

Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109. https://doi.org/10.1111/j.1365-2125.2008.03308.x.CrossRefPubMedPubMedCentral

26.

Myasoedova E, Karmacharya P, Duarte-Garcia A, Davis JM 3rd, Murad MH, Crowson CS. Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1348–56. https://doi.org/10.1016/j.semarthrit.2020.03.008.CrossRefPubMed

27.

OptumLabs. OptumLabs Data Warehouse (OLDW) Descriptions and Citation. Cambridge, MA 2019.

28.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019;73(24):3168–209. https://doi.org/10.1016/j.jacc.2018.11.002.CrossRefPubMed

29.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8.CrossRefPubMed

30.

Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical care. 1998;36(1):8–27. https://doi.org/10.1097/00005650-199801000-00004.CrossRefPubMed

31.

Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168–74. https://doi.org/10.1164/rccm.201902-0456OC.CrossRefPubMed

32.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84. https://doi.org/10.1038/nature01158.CrossRefPubMed

33.

Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine. 2005;15(6):202–6. https://doi.org/10.1016/j.tcm.2005.07.002.CrossRefPubMed

34.

Noël B. Statins and lupus erythematosus. Rheumatology. 2004;43(3):397–8.CrossRef

35.

Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481–90. https://doi.org/10.1136/jcp.56.7.481.CrossRefPubMedPubMedCentral

36.

Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity – friends or foes? Trends Immunol. 2009;30(8):409–14. https://doi.org/10.1016/j.it.2009.05.005.CrossRefPubMed

37.

Jones KD, Couldwell WT, Hinton DR, Su YH, He SK, Anker L, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun. 1994;205(3):1681–7. https://doi.org/10.1006/bbrc.1994.2861.CrossRefPubMed

38.

Blanco-Colio LM, Villa A, Ortego M, Hernández-Presa MA, Pascual A, Plaza JJ, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161(1):17–26. https://doi.org/10.1016/S0021-9150(01)00613-X.CrossRefPubMed

39.

Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol. 2003;31(9):779–83. https://doi.org/10.1016/S0301-472X(03)00192-9.CrossRefPubMed

40.

Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508–19. https://doi.org/10.1038/sj.leu.2402476.CrossRefPubMed

41.

Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152(1):217–27. https://doi.org/10.1016/S0021-9150(99)00462-1.CrossRefPubMed

42.

Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol. 2001;144(5):958–66. https://doi.org/10.1046/j.1365-2133.2001.04182.x.CrossRefPubMed

43.

Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, et al. Remnants of suicidal cells fostering systemic autoaggression: apoptosis in the origin and maintenance of autoimmunity. Arthritis & Rheumatism. 2000;43(8):1663–72. https://doi.org/10.1002/1529-0131(200008)43:8<1663::AID-ANR1>3.0.CO;2-1.CrossRef

44.

Van Halm V, Nielen M, Nurmohamed M, Van Schaardenburg D, Reesink H, Voskuyl A, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):184–8. https://doi.org/10.1136/ard.2006.051672.CrossRefPubMed

45.

Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(4):792–7. https://doi.org/10.1161/ATVBAHA.107.159749.CrossRefPubMed

46.

Van Oostrom A, Rabelink T, Verseyden C, Sijmonsma T, Plokker H, De Jaegere PT, et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis. 2004;177(1):175–82. https://doi.org/10.1016/j.atherosclerosis.2004.07.004.CrossRefPubMed

47.

Meijssen S, Van Dijk H, Verseyden C, Erkelens D, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2002;22(5):811–6. https://doi.org/10.1161/01.ATV.0000014079.98335.72.CrossRefPubMed

48.

Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994;37(6):814–20. https://doi.org/10.1002/art.1780370606.CrossRefPubMed

49.

Sathasivam S, Lecky B. Statin induced myopathy. Bmj. 2008;337(nov06 3):a2286. https://doi.org/10.1136/bmj.a2286.CrossRefPubMed

50.

Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 1997;40(11):1955–61. https://doi.org/10.1002/art.1780401106.CrossRefPubMed

51.

Di Giuseppe D, Bottai M, Askling J, Wolk A. Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study. Arthritis Res Ther. 2015;17(1):1–7.CrossRef

Title: Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study
Authors: Madeline N. Peterson
Hayley J. Dykhoff
Cynthia S. Crowson
John M. Davis III
Lindsey R. Sangaralingham
Elena Myasoedova
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Statins
Methotrexate
Methotrexate
Rheumatoid Arthritis
Published in: Arthritis Research & Therapy / Issue 1/2021
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-021-02617-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Functional analysis of novel A20 variants in patients with atypical inflammatory diseases

Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis

Development of a model for predicting the 4-year risk of symptomatic knee osteoarthritis in China: a longitudinal cohort study

Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

Intradiscal injection of monosodium iodoacetate induces intervertebral disc degeneration in an experimental rabbit model

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials